GlassScriptPhysician profile
Esmaeil Sebti
NPI 1194728881
$15,033.69
in general payments reported to CMS, 2019-2025
45 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $563 · 2021: $2,062 · 2022: $1,847 · 2023: $2,945 · 2024: $3,625 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,152 · Consulting Fee: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,151.82 |
| Consulting Fee | $2,130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,060.68 | 2019-2025 | Zilbrysq, Rystiggo |
| Abbvie INC. | $1,591.52 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Neurocrine Biosciences, INC. | $1,356.55 | 2019-2025 | Ingrezza |
| Biogen, INC. | $829.22 | 2019-2025 | Vumerity, Leqembi |
| Alexion Pharmaceuticals, INC. | $827.48 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $410.09 | 2019-2024 | Gocovri, Apokyn |
| Tg Therapeutics, INC. | $408.83 | 2023-2025 | |
| Abbott Laboratories | $382.61 | 2021-2023 | Infinity |
| Grifols USA, LLC | $367.18 | 2019-2024 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $362.60 | 2019-2025 | Austedo Xr |
| Argenx US, INC. | $334.78 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Adamas Pharmaceuticals, INC. | $290.23 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $277.13 | 2021 | |
| Amgen INC. | $238.74 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $223.11 | 2019-2025 | Crexont, Rytary |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $214.52 | 2022-2025 | Xeomin |
| Allergan, INC. | $203.21 | 2019-2022 | |
| Kyowa Kirin, INC. | $201.64 | 2019-2024 | Nourianz |
| Genentech USA, INC. | $171.23 | 2019-2024 | Ocrevus |
| Boston Scientific Corporation | $167.67 | 2023-2024 | Watchman Flx, Versacross Access Solution |
| Lundbeck LLC | $163.46 | 2019-2022 | |
| Amylyx Pharmaceuticals, INC. | $161.42 | 2023-2024 | Relyvrio |
| Janssen Scientific Affairs, LLC | $152.81 | 2022 | |
| Genzyme Corporation | $145.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $144.98 | 2024 | |
| Sk Life Science, INC. | $138.21 | 2022 | |
| Lilly USA, LLC | $132.84 | 2019-2025 | Kisunla, Amyvid |
| Emd Serono, INC. | $125.00 | 2023 | Mavenclad |
| Alnylam Pharmaceuticals INC. | $121.36 | 2023 | Amvuttra |
| Impel Pharmaceuticals INC. | $114.67 | 2022 | |
| Octapharma USA, INC. | $105.20 | 2024 | Panzyga |
| Eisai INC. | $103.00 | 2019-2023 | |
| Pfizer INC. | $64.89 | 2024-2025 | |
| Acorda Therapeutics, INC | $64.80 | 2020-2022 | |
| Axsome Therapeutics, INC. | $59.19 | 2025 | Symbravo |
| Tanabe Pharma America, INC. | $58.28 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $51.18 | 2019-2024 | Nuplazid |
| Janssen Pharmaceuticals, INC | $46.21 | 2022 | |
| Merz North America, INC. | $38.25 | 2019-2020 | |
| Livanova USA, INC. | $24.26 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Avion Pharmaceuticals | $23.16 | 2023 | Dhivy |
| Owp Pharmaceuticals, INC. | $21.11 | 2025 | Subvenite |
| Harmony Biosciences LLC | $19.77 | 2023 | Wakix |
| Strongbridge US INC. | $18.58 | 2019 | |
| Cala Health, INC. | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esmaeil Sebti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.